Scripps research team unravels new cellular repair mechanismAugust 07, 2008Work in yeast cells could lead to similar discovery in humans and new cancer treatments The research was published today in an advanced, online issue of the Proceedings of the National Academy of Sciences. The cell cycle, which allows cells to replicate their DNA and produce new cells, is controlled by a complex concert of enzymes and other components. In addition there are "checkpoint" mechanisms that can block continuation of the process if something goes amiss. Via mechanisms still poorly understood, a checkpoint in the reproduction process can detect problems that interfere with DNA copying. This detection can in turn trigger several potential responses.
"If the cycle is paused because the cell is having some problem," says study lead Professor Curt Wittenberg, of the Scripps Research Departments of Molecular Biology and Cell Biology, "it can't stop and go back, so it either kills the new cell or repairs the problem." The checkpoint mechanisms that control the cell cycle are of great interest not only because they are such a fundamental aspect of biology, but also because problems in the cycle and its DNA repair mechanisms can lead to mutations that cause the unchecked proliferation of cells associated with various cancers. The Wittenberg group recently identified a protein dubbed Nrm1 that appeared to play important roles in a yeast cell's successful transition from the G1 phase, in which cells prepare to replicate DNA, to actual replication during the S phase. Now, in the new paper, the Wittenberg group in collaboration with colleagues in the Scripps Research laboratories of Professors Paul Russell and John Yates show what some of those roles are. At specific points in the cell cycle, groups of genes are turned on and off to produce the enzymes and other components needed for progression into the next cell cycle phase, and a healthy cell will only move forward into the next phase of the cycle if certain standards are met. However, if a problem arises in the DNA replication process during the S phase, the entire process stalls. "If either the replicating enzymes run into damage, or if there are insufficient precursors for making DNA, then this checkpoint response will be activated," says Wittenberg. "There are two aspects to this response. One is to prevent the cycle from proceeding, and the other is to prepare the cell to deal with the damage." Wittenberg and his colleagues have found that during normal cell division, Nrm1's binding to DNA represses the activity of genes expressed during the G1 phase, in preparation for the subsequent S phase. The team has now shown that when such stalls occur, collectively referred to as DNA stress, Nrm1's repression of the G1 genes is blocked, allowing those genes to be turned back on. This presumably enables production of proteins needed to correct the problem that caused the stall. "So, now you have cells in the S phase, which don't typically express these genes, expressing them," says Wittenberg. The researchers were able to tease out Nrm1's specific activities through experiments where they intentionally blocked the cell cycle in yeast cells by robbing them of the precursors needed for DNA replication. They were able to show that, as a result of this induced stress, Nrm1 was chemically altered by a known checkpoint enzyme, resulting in the loss of binding to G1 genes. This resulted in expression of the G1 genes during S phase. Because those genes encode replication and repair enzymes, re-expression of the G1 genes facilitates re-starting of DNA replication. Because the onset of cancer is so intimately tied to problems in the cell cycle, numerous cancer drugs currently under development target checkpoint mechanisms, with the goals of making cells more sensitive to chemotherapeutic agents that damage DNA, and in some cases protecting normal proliferating cells from cell cycle arrest and death. Given that, once Nrm1's human analog and its activity are identified, Wittenberg and his colleagues are hopeful the information could provide fruitful targets for new cancer therapies tied to the mechanism involved. Scripps Research Institute | |||||||||||||||||||||
|
Related Cell Cycle Current Events and Cell Cycle News Articles Could vitamin D save us from radiation? Radiological health expert Daniel Hayes, Ph.D., of the New York City Department of Health and Mental Hygiene suggests that a form of vitamin D could be one of our body's main protections against damage from low levels of radiation. Study links nicotine with breast cancer growth and spread A study published in Cancer Research, a journal of the American Association for Cancer Research, suggests a possible role for nicotine in breast tumor development and metastases. Cancer-causing gut bacteria exposed Normal gut bacteria are thought to be involved in colon cancer but the exact mechanisms have remained unknown. Now, scientists from the USA have discovered that a molecule produced by a common gut bacterium activates signalling pathways that are associated with cancer cells. Stem cell regeneration repairs congenital heart defect Mayo Clinic investigators have demonstrated that stem cells can be used to regenerate heart tissue to treat dilated cardiomyopathy, a congenital defect. International team reveals first prognosticator of survival in aggressive cancer The tumor suppressor gene pRb2/p130 may provide the first independent prognostic biomarker in cases of soft tissue sarcoma (STS). CSHL scientists identify new drug target against virulent type of breast cancer Tumor cells in a particular subset of breast cancer patients churn out too much of a protein called ErbB2 -- also often called HER2 -- which drives the cells to proliferate unchecked. Patients unlucky enough to be in this group -- about one in four -- have poorer prognoses and clinical outcomes than those who don't. Protein key to control, growth of blood cells New research sheds light on the biological events by which stem cells in the bone marrow develop into the broad variety of cells that circulate in the blood. The findings may help improve the success of bone marrow transplants and may lead to better treatments for life-threatening blood diseases. Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the efficacy of imiquimod, a clinically important immune response modifier with potent antiviral and antitumor activity, is dependent on the Opioid Growth Factor (OGF)-OGF receptor (OGFr) axis for its action. Novel structure proteins could play a role in apoptosis Isoforms from Novel Structure Proteins (NSP), a new family of genes discovered by researchers in the Sbarro Institute for Cancer Research and Molecular Medicine in Temple University's College of Science and Technology, could be involved in apoptosis or programmed cell death. UGA researchers discover mechanism that explains how cancer enzyme winds up on ends of chromosomes Human cancer cells divide and conquer. Unless physicians can control that division with surgery, chemotherapy or radiation, the wildly dividing cells will eventually destroy a person's life. More Cell Cycle Current Events and Cell Cycle News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||